Skip to content

Vestibular Incision Subperiosteal Tunnel Access With Fascia Lata Allograft in The Treatment of Gingival Recession

Evaluation The Efficacy of Vestibular Incision Subperiosteal Tunnel Access With Fascia Lata Allograft in The Treatment of Gingival Recession A Randomized Controlled Clinical Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07467096
Enrollment
24
Registered
2026-03-12
Start date
2024-03-01
Completion date
2025-09-01
Last updated
2026-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingival Recession

Brief summary

The present study will be conducted as a randomized controlled clinical study to assess to evaluate the effect of minimally invasive VISTA with fascia lata allograft in the treatment of gingival recession

Interventions

OTHERVestibular incision sub-periosteal tunnel access + fascia lata

The vestibular incision sub-periosteal tunnel access (VISTA) technique for all groups will be done and the patients will receive VISTA techniques with fascia lata

OTHERVestibular incision sub-periosteal tunnel access + subepithelial connective tissue graft

The vestibular incision sub-periosteal tunnel access (VISTA) technique for all groups will be done and the patients will receive VISTA techniques with subepithelial connective tissue graft CTG

Sponsors

Hams Hamed Abdelrahman
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Presence of gingival recession type 1 (RT1) Cairo classification (6) * Gingival recession depth ≥ 2 mm. * Gingival thickness for the site selected should be ≥1mm. * The height of keratinized gingiva (HKG) for the site selected should be ≥2 mm (HKG is the distance between the most apical point of the gingival margin and the mucogingival junction). * Optimal compliance as evidenced by no missed treatment appointments and a positive attitude toward oral hygiene.

Exclusion criteria

* Presence of any systemic disease that could influence the outcome of the therapy. * Presence of any risk factor e.g.; smoker, pregnant and lactating patients. * Previous history of periodontal surgical treatment in quadrant selected for the study. * Restorations or caries in the area to be treated and non-vital tooth. * Teeth which are tilted or rotated. * Patients taking medications known to cause gingival enlargement.

Design outcomes

Primary

MeasureTime frameDescription
change in Gingival recession depth2 weeks, 3 months, 6 monthswill be measured at the mid-buccal aspect of the tooth from the (CEJ) to the most apical point of the gingival margin (GM).
change in Gingival recession width (GRW)2 weeks, 3 months, 6 monthsit will be measured at the mesiodistal direction of the GM at the level of CEJ

Secondary

MeasureTime frameDescription
change in Keratinized tissue width (KTW)2 weeks, 3 months, 6 monthswill be measured as the distance between the GM and the mucogingival junction (MGJ)
change in Clinical attachment loss (CAL)2 weeks, 3 months, 6 monthswill be measured at the mid-buccal aspect of the tooth from CEJ to the bottom of the sulcus.
change in Probing depth (PD)2 weeks, 3 months, 6 monthsit will be measured from the GM to the bottom of the sulcus.
change in Gingival thickness (GT)2 weeks, 3 months, 6 monthsit will be measured at the mid-buccal aspect of a treated tooth on the long axis, 3 mm apically from the GM using K-file 25 ISO with a silicon marker driven perpendicularly to the gingival surface after application of local anesthesia.
change in Recession esthetic score (RES)2 weeks, 3 months, 6 monthsit evaluates five outcome variables (GM level, marginal tissue contour, soft tissue texture, MGJ alignment, and gingival color) leading to a final score ranging from 0 to 10 points.
change in Percentage of root coverage (RC)2 weeks, 3 months, 6 monthsit will be calculated at 3 and 6 months post- operative by the following formula: (GRD baseline - GRD 3/6 months)/GRD baseline × 100%

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026